Ahmad, Harris A. https://orcid.org/0000-0002-0890-2071
Baker, Joshua F.
Conaghan, Philip G.
Emery, Paul
Huizinga, Thomas W. J.
Elbez, Yedid
Banerjee, Subhashis
Østergaard, Mikkel
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Received: 6 July 2021
Accepted: 27 December 2021
First Online: 16 February 2022
Declarations
:
: This study was carried out in accordance with the Declaration of Helsinki. The AVERT study protocol was approved by the Institutional Review Board or Independent Ethics Committee at each site []. All study participants provided informed consent for involvement in the study.
: Not applicable
: Professor Conaghan has received grant/research support from Bristol Myers Squibb, consulting fees from AbbVie, GlaxoSmithKline, Eli Lilly, Novartis, Pfizer, and Roche, and speaking fees from AbbVie, Bristol Myers Squibb, and Novartis. Professor Emery has received consulting fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Samsung Bioepis. Professor Huizinga has received grant/research support from the EU & Dutch Arthritis Foundation, consulting fees from Abbott Laboratories, Biotest AG, Bristol Myers Squibb, Crescendo Biosciences, Eli Lilly, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, and UCB, and speaking fees from Abbott Laboratories, Biotest AG, Bristol Myers Squibb, Novartis, Pfizer, Pharmaceuticals Corporation, Roche, Sanofi-Aventis, and Schering-Plough. Mr. Elbez received consulting fees from Bristol Myers Squibb. Dr. Banerjee is an employee of and shareholder in Bristol Myers Squibb. Professor Østergaard has received grant/research support from AbbVie, Bristol Myers Squibb, Janssen, and Merck, and speaking fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Eli Lilly, GlaxoSmithKline, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Schering-Plough, Takeda, UCB, and Wyeth.Dr. Ahmad is an employee of Bristol Myers Squibb. Dr. Baker has received consulting fees from Bristol Myers Squibb.